Gary S. Gillheeney Sells 41,052 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) Stock

Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Gary S. Gillheeney sold 41,052 shares of the stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $3.52, for a total transaction of $144,503.04. Following the sale, the chief executive officer now directly owns 3,359,726 shares in the company, valued at $11,826,235.52. This trade represents a 1.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Organogenesis Stock Up 5.1 %

NASDAQ:ORGO opened at $3.68 on Wednesday. The stock’s fifty day moving average price is $3.39 and its two-hundred day moving average price is $2.98. The company has a market cap of $487.89 million, a price-to-earnings ratio of -61.33 and a beta of 1.73. Organogenesis Holdings Inc. has a 52-week low of $2.16 and a 52-week high of $4.70. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.11. The business had revenue of $115.18 million for the quarter, compared to analysts’ expectations of $109.59 million. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. During the same quarter last year, the business earned $0.02 earnings per share. On average, analysts anticipate that Organogenesis Holdings Inc. will post -0.07 EPS for the current year.

Institutional Investors Weigh In On Organogenesis

Several institutional investors have recently modified their holdings of ORGO. Captrust Financial Advisors acquired a new position in Organogenesis in the third quarter valued at approximately $36,000. Pallas Capital Advisors LLC bought a new position in shares of Organogenesis in the 2nd quarter worth $38,000. Delap Wealth Advisory LLC acquired a new stake in shares of Organogenesis during the second quarter worth $40,000. Intech Investment Management LLC bought a new stake in Organogenesis in the third quarter valued at about $43,000. Finally, Allspring Global Investments Holdings LLC lifted its stake in Organogenesis by 4,989.9% in the second quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company’s stock valued at $44,000 after buying an additional 15,369 shares during the period. Institutional investors and hedge funds own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.